메뉴 건너뛰기




Volumn 20, Issue 24, 2010, Pages 7323-7326

Antiangiogenic properties of substituted (Z)-(±)-2-(N-benzylindol-3- ylmethylene)quinuclidin-3-ol/one analogs and their derivatives

Author keywords

Angiogenesis; Antiangiogenic activity; Enox1; Human Umbilical Vein Endothelial Cells; Indole; Substituted (Z) ( ) 2 (N benzylindol 3 ylmethylene) quinucli din 3 ol one analogs

Indexed keywords

(2 BENZYLINDOL 3 YLMETHYLENE)QUINUCLIDIN 3 ONE DERIVATIVE; 2 (1H/N METHYL INDOL 3 YLMETHYLENE)QUINUCLIDIN 3 OL DERIVATIVE; 2 (N BENZENESULFONYLINDOL 3 YL METHYLENE)QUINUCLIDIN 3 OL DERIVATIVE; 2 (N BENZYLINDOL 3 YLMETHYLENE)QUINUCLIDIN 3 OL DERIVATIVE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; QUINUCLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

EID: 78449304270     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.10.060     Document Type: Article
Times cited : (14)

References (17)
  • 2
    • 0004027213 scopus 로고    scopus 로고
    • D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, R.C. Bast Jr. Gansler, J.F. Holland, J.F. Holland, T.S.*Frei E. III BC Decker Hamilton, Canada
    • D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, R.C. Bast Jr. T.S. Gansler, J.F. Holland, J.F. Holland, Emil Frei III Cancer Medicine 2003 BC Decker Hamilton, Canada
    • (2003) Cancer Medicine
  • 4
    • 78449272167 scopus 로고    scopus 로고
    • FDA Approval Summary for Bevacizumab - National Cancer Institute. November 10
    • FDA Approval Summary for Bevacizumab - National Cancer Institute. November 10, 2008 http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab.
    • (2008)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.